13D Filing: Coliseum Capital and Bioscrip Inc. (BIOS)

Page 2 of 10

Page 2 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Coliseum Capital Management, LLC

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

AF

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

24,208,030 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

24,208,030 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

24,208,030 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

16.5% (1)

14.

Type of Reporting Person (See
Instructions)

IA

(1) Includes (a) 4,735,932 shares of common stock, $0.0001 par value per share (the Common Shares), (b) 274,854 Common Shares that could be obtained upon conversion of 10,823 shares of Series A Convertible
Preferred Stock, par value $0.0001 per share at a conversion price of $5.17 per share (the Series A Preferred Shares), (c) 15,597,245 Common Shares that could be obtained upon conversion of 614,177 shares of Series C Convertible
Preferred Stock, par value $0.0001 per share at a conversion price of $5.17 per share (the Series C Preferred Shares), (d) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class A warrants to purchase
Common Shares at a price of $5.17per share (the Class A Warrants), and (e) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class B warrants to purchase Common Shares at a price of $6.45 per
share (the Class B Warrants and, together with the Class A Warrants, the Warrants).

Page 2 of 10

Follow Option Care Health Inc. (NASDAQ:OPCH)

Page 2 of 10